Ultimovacs ASA (Norway) Performance
| ULTI Stock | NOK 2.03 0.03 1.50% |
The entity has a beta of 0.75, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Ultimovacs ASA's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ultimovacs ASA is expected to be smaller as well. At this point, Ultimovacs ASA has a negative expected return of -0.47%. Please make sure to validate Ultimovacs ASA's kurtosis, daily balance of power, and the relationship between the skewness and accumulation distribution , to decide if Ultimovacs ASA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ultimovacs ASA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's essential indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 440.9 M | |
| Total Cashflows From Investing Activities | 3 M |
Ultimovacs |
Ultimovacs ASA Relative Risk vs. Return Landscape
If you would invest 276.00 in Ultimovacs ASA on December 18, 2024 and sell it today you would lose (73.00) from holding Ultimovacs ASA or give up 26.45% of portfolio value over 90 days. Ultimovacs ASA is generating negative expected returns and assumes 3.2817% volatility on return distribution over the 90 days horizon. Simply put, 29% of stocks are less volatile than Ultimovacs, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Ultimovacs ASA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ultimovacs ASA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ultimovacs ASA, and traders can use it to determine the average amount a Ultimovacs ASA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1421
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ULTI |
Estimated Market Risk
| 3.28 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ultimovacs ASA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ultimovacs ASA by adding Ultimovacs ASA to a well-diversified portfolio.
Ultimovacs ASA Fundamentals Growth
Ultimovacs Stock prices reflect investors' perceptions of the future prospects and financial health of Ultimovacs ASA, and Ultimovacs ASA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ultimovacs Stock performance.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 3.35 B | |||
| Shares Outstanding | 34.4 M | |||
| Price To Book | 7.44 X | |||
| EBITDA | (161.69 M) | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 11.95 X | |||
| Total Debt | 457 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 14.97 X | |||
| Cash Flow From Operations | (125.83 M) | |||
| Earnings Per Share | (5.09) X | |||
| Total Asset | 655.54 M | |||
About Ultimovacs ASA Performance
By examining Ultimovacs ASA's fundamental ratios, stakeholders can obtain critical insights into Ultimovacs ASA's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Ultimovacs ASA is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.Things to note about Ultimovacs ASA performance evaluation
Checking the ongoing alerts about Ultimovacs ASA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ultimovacs ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ultimovacs ASA generated a negative expected return over the last 90 days | |
| Ultimovacs ASA has high historical volatility and very poor performance | |
| Ultimovacs ASA has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (164.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ultimovacs ASA has accumulated about 1.85 M in cash with (125.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 48.0% of the company outstanding shares are owned by insiders |
- Analyzing Ultimovacs ASA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ultimovacs ASA's stock is overvalued or undervalued compared to its peers.
- Examining Ultimovacs ASA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ultimovacs ASA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ultimovacs ASA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ultimovacs ASA's stock. These opinions can provide insight into Ultimovacs ASA's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.